Sera from 67 patients treated for renal diseases were assayed by as many as three different tests for activities against Mason-Pfizer virus (M-P V) antigens. Firstly, in patients studied before kidney transplantation, neutralizing activity against syncytium-forming units of M-P V was found in 5o ~ of z4 cases of chronic glomerulonephritis but in only Io ~ of zo cases with other diseases (P < o'o0. These proportions were higher after treatments accompanying transplantation since, of the I9 patients without antibodies before graft, 53 ~ showed a seroconversion after this treatment. The incidence ofM-P V antibodies did not correlate with the number of transfusions received by the patients. Neither did these antibodies correlate with the presence of antibodies to antigens associated with baboon endogenous virus or simian sarcoma virus; antibodies to the latter two viruses were found in 6 to 2i ~ of the sera, with no specific distribution among the sera. Secondly, pseudotypes of vesicular stomatitis virus with M-P V antigens in their envelope were prepared; they were inactivated by 9o ~ of the sera which neutralized M-P V syncytium forming units and by none of the negative sera. Thirdly, specific complement-dependent cytotoxic antibodies to HeLa cells producing M-P V were also found in 61 ~ of the sera with neutralizing activity to M-P V and only in 12 ~ of the sera which did not neutralize M-P V. Absorption experiments indicated that the serum activities against M-P V associated antigens were not due to anticellular antibodies directed against normal constituents of human cells. However, no evidence has been provided that the M-P V associated antigens reacting with the human sera were virus coded.
INTRODUCTION
In our laboratory, an oncornavirus with all the properties of Mason-Pfizer virus (M-P V) has been obtained after co-culture of SIRC cells with the leukocytes of a patient who had been treated with two successive kidney transplants (Thiry et al. I978a) . However, the possibility existed that contamination of the human leukocyte cultures with laboratory strains of M-P V could have occurred. In order to determine whether human individuals can indeed be infected with a Mason-Pfizer-like virus, and whether this occurs more frequently in renal diseases or after kidney transplantation, we assayed the sera from a few groups of individuals for the presence of antibodies to antigens of M-P V. Antibodies were tested by three methods: inhibition of the ability of M-P V to form syncytia on KC cells (Ahmed et al. I974) and neutralization of the plaque-forming units (p.f.u.) of pseudotypes of vesicular stomatitis virus (VSV) containing antigens of M-P V in their envelope (Alstein et al. 1976 ; Thiry et al. I978 c) . A proportion of sera were also assayed for complement-dependent cytotoxic antibodies to cells chronically producing M-P V.
Patients with immune complex chronic glomerulonephritis were compared to patients with other renal diseases, because of indications that oncornavirus antigens may be present in the glomeruli of human systemic lupus erythematosus (Mellors & Mellors, I976; Panem et al. 1976) . When available, sera were compared before and after kidney transplantation, since allogeneic antigens stimulate the expression of oncornaviruses in mice (Hirsch et al. 197o, 1972 (Hirsch et al. 197o, , 1973 .
The specificity of serum neutralizing activity against M-P V syncytium p.f.u, was checked by comparing this activity with that against syncytium p.f.u, of baboon type C oncornavirus (BeV) on KC cells (Ahmed et al. I975 ) and of Simian sarcoma virus (SSV) on XC cells (Kawakami et al. I972) . VSV pseudotypes with baboon C virus antigens were also obtained and were compared to VSV (M-P V) pseudotypes in neutralization tests with adult sera.
The present investigation demonstrates the presence of human antibodies with specificities to antigens related with M-P V infection. Our previous results also indicated that M-P V related antigens may be expressed in humans, since some pregnant women showed cell-mediated immune recognition of these antigens (Thiry et al. I978b ) .
METHODS

Human groups.
Sixty seven patients attending a kidney unit at the Free University of Brussels were studied. Of these, 35 suffered from immune complex chronic glomerulonephritis and 32 from other renal diseases. Of the 5 ° patients who received renal transplants, 27 were studied I to 4 weeks before kidney transplantation and then 2 to IO months after graft. Only post-transplant sera were available from 23 patients. An additional group of I7 patients were studied who were not treated by kidney transplantation. In addition to these adult patients, 25 children 3 to 6 years of age, hospitalized for a respiratory disease, were also studied.
Viruses and cells. The sources of M-P V were HeLa E cells, from Essen (Gelderblom et al. I974) provided by H. Gelderblom, and the human lymphoblast cell line NC37 chronically infected with M-P V, obtained from D. Fine. Dog thymus cells infected with BeV were received from D. Lowy and normal rat kidney, NRK infected with SSV, from H. Gelderblom. The same cell lines with no detectable oncornavirus particle or reverse transcriptase activity were received as controls. KC human cells carrying Rous virus genone were purchased from Flow Laboratories and XC rat cells with the same genome were provided by S. Cross.
To prepare pseudotypes, VSV (Indiana strain) was inoculated at a m.o.i, of I to HeLa or NC37 cells chronically infected with M-P V, or to dog thymus cells carrying the baboon C particle virus. After 48 h growth at 37 °C, virus preparations were clarified by low speed centrifugation.
Rabbit antisera. For the preparation of virus antigen, oncornavirus carrying cells were grown in monolayers in roller bottles for 48 h. Viruses were purified from the supernatant as described (Schochetman et at. 1975) andused to inoculate rabbits, which received 4 weekly intradermal injections of 0"5 ml virus preparation plus complete Freund's adjuvant. Bleeding was performed 8 days after the last injection. Anti-M-P V and anti-BeV sera were adsorbed with HeLa and dog cells respectively. After they were treated with 2 x IO v cells/ml for I h at 37 °C and then t8 h at 4 °C, the cells were centrifuged. The adsorption procedure was repeated twice more.
Treatment of human sera. All sera were heated for 3o rain at 56 °C and stored at -2o °C.
in some experiments, the sera were adsorbed with HeLa or NC37 cells, as described for the rabbit antisera. A human cell suspension was also obtained after action of trypsin on three 6 week old human foetuses and used for similar adsorptions of some patients' sera. In other experiments, the globulin fraction from I ml of serum was precipitated by the addition of an equal vol. of 4 M-ammonium sulphate at pH 7"3. The proteins were collected at 5ooog for 5 rain and washed three times in 2 M-ammonium sulphate and then redissolved in sterile distilled water. The solution was extensively dialysed in PBS, pH 7-2, and sterilized by Millipore filtration. Plaque assays. For the titration of VSV, primary chick embryo fibroblasts were grown in io 3 sterilin dishes IOOX I8O mm square with 25 compartments, each compartment was inoculated with 0"5 ml of virus diluted in Dulbecco modified Eagle's medium with a heated foetal calf serum. After incubation for I h at 37 °C, I ml of the same medium with z ~o methylceUulose was added per compartment and the cultures were stained with neutral red after z days at 37 °C. For syncytial assays of oncornavirus, a direct virus inoculation test was used (Rand & Long, I972; Ahmed et al. I974, I975) ; flat bottomed wells of microplates were inoculated with 20o #1 of culture medium containing 2 x io 4 KC or XC cells; subconfluent monolayers of cells obtained after a4 to 48 h growth at 37 °C in a humidified incubator with 5 ~ COs atmosphere were washed once and inoculated with zoo/~1 of clarified supernatants from 3 day old cell cultures producing oncornaviruses. These supernatants were diluted I:~, I : 5 and I : 20 and added to eight wells per dilution. The plaques were read after incubation for 48 h, fixation with methanol and staining with May-Grtinwald-Giemsa. The microplates were screened under a microscope equipped with a Dynascope (Vision Engineering Ltd). In the controls, a few syncytia with 4 nuclei were seen, with rare (~ to 3 per 8 wells) syncytia with a larger number of nuclei. In cells infected with oncornavirus, syncytia with 6 to Io nuclei were counted. There were from 70 to 5oo of these syncytia per ml in the supernatants of cells producing the oncornaviruses.
Neutralization tests. Fifty #1 of VSV, grown in oncornavirus infected or in control cells, were mixed with the same volume of heated serum and incubated for 2 h at 4 °C. The mixtures were then serially diluted and the plaques counted. Inhibition of syncytium formation was assayed after I h contact at 37 °C of serum at final dilution I :Io and an amount of virus adjusted to produce about Io to I4 syncytia of more than 5 nuclei/well, containing KC or XC monolayers; 8 wells were inoculated and the mean+ standard deviation was calculated. When this mean was statistically lower (P < o'o0 than the mean obtained with virus alone, the serum was recorded as showing neutralizing activity and the percentage of syncytium-forming units which escaped neutralization was calculated after the formula:
(syncytia caused by virus + serum mixture)-syncytia in uninoculated cells × I00
(syncytia caused by virus) -syncytia in uninoculated cells
Assay for complement-dependent cytotoxic antibodies. A short term microcytotoxicity assay was applied (Kurth & Medley, I975) . A suspension containing 5 x io 4 target cells/ml was mixed with 50 #Ci/ml of 51Cr sodium chromate (sp. act. r35 mCi/mg) and samples of 2o/~I were distributed in microtest tissue culture plates (Falcon Plastic 3o34). After cultivation for I8 h at 37 °C in a humidified incubator with a 5 ~o CO2 atmosphere, the plates 38-2 were turned upside down, medium was drained with a blotting paper and the wells were washed twice with PBS. Five #1 of heated human serum diluted I" IO, I : IOO, I " IOOO were distributed in three wells per serum dilution. After I5 min at 37 °C, 2 #1 of fresh guinea-pig serum were added to each well and the plates were further incubated for 3o min at 37 °C. Five #1 of the mixture were promptly collected from each well and radioactivity counted in a Packard auto-gamma scintillation spectrometer. Two Sera from 5 to Io year old children were tested as controls. In five wells serum was replaced by 5 #1 of PBS. Total radioactivity of the target cells was measured after treatment with 5 ~ sodium dodecylsulphate (SDS) for 45 rain at 37 °C. The percentage of 51Cr release was calculated according to the formula:
(ct/min after patient serum + C)-(ct/min after child sera + C) x Ioo (ct/min after SDS) -(ct/min after child sera + (2)
Where C = fresh guinea-pig serum. The mean of the results obtained with two child sera was calculated and did not vary by more than Io ~ from the results obtained with complement alone.
RESULTS
Detailed demonstration of specific neutralizing antibodies to oneornaviruses in two human sera
A rabbit antiserum prepared against purified M-P V inactivated 54 ~ of the VSV (M-P V) pseudotypes and 85 ~ of M-P V syncytium forming units, with no activity on viruses with BeV antigens (Table I) . Serum from patient I showed neutralizing activities similar to those of the rabbit antiserum. Conversely, serum from patient 2 as well as the serum from a rabbit hyperimmunized to BeV specifically reacted with VSV (BeV) pseudotypes and with syncytium-forming units of BeV. VSV grown in various cell lines documented for the absence of oncornavirus were not neutralized by the sera.
Since these patients' sera were obtained from kidney grafted patients, it was possible that they contained various competing antigens released from the graft and possibly some polypeptides related to oncornavirus antigens. If so, these antigens might bind to receptors of M-P V or of BeV present at the surface of KC cells and thus block syncytium formation by the virions added in the experiments. To test this hypothesis, we pre-treated the KC cells * ~ of syncytium forming units remaining after contact with serum for I h at 37 °C, as compared to syncytia formed after incubation of M-P V with PBS.
M-P V neutralization by human sera
59I
t Serum was left in contact with KC cells for I h at 37 °C, then the cells were washed and M-P V was added.
for I h at 37 °C with undiluted human serum and then washed the cells and added M-P V or BeV. This pre-treatment did not reduce syncytium formation by M-P V or BeV indicating that the inhibitory activities of the sera were probably not due to competing antigens.
It has been shown that an inhibitor in normal mouse sera inactivates murine xenotropic oncornaviruses (Fischinger et al. I976) . It was therefore necessary to investigate whether the neutralizing activities shown here were in the globulin fraction. This fraction was precipitated with ammonium sulphate from the sera of patients I and z and the inhibitory activity was conserved. It was on the other hand abolished after treatment with an equal vol. of goat antiserum to human immunoglobulin (Hyland) for I h at 37 °C and I8 h at 4 °C. There was still the possibility that human IgG present in the patients' sera were directed against cell antigens incorporated into M-P V and BeV envelopes, rather than against virus structural proteins. Since the neutralization tests were performed with M-P V grown in HeLa cells and with BeV replicated in dog thymus cells, sera from patients I and z were adsorbed with HeLa and dog cells, respectively, and re-assayed for virus neutralization. Adsorbed sera had retained their neutralizing activities. In another experiment, the patients' sera were adsorbed with human foetal cells and this procedure did not remove the neutralizing activities.
The results concerning serum from patient r are summarized in Table 2 . About 5 to Io of the sera studied in the following paragraph were submitted to the same control tests.
Distribution of neutralizing antibodies to M-P V, BeV and SSV antigens among patients
Fig . I illustrates the results of two tests applied for the detection of antibodies to M-P V antigens. There was a good correlation between the demonstration of neutralizing antibodies to syncytium-forming units of M-P V and that of antibodies to VSV (M-P V) pseudotypes. The former test was positive in I2 of 24 (5 ° ~) patients with chronic glomerulonephritis studied before transplantation and only in 2 of 20 (IO ~oo) of those with other renal diseases (P < o.oI). On the other hand, seroconversions after kidney transplantation were found in Io of I9 (53 ~) patients without antibody before graft (Table 3) .
In order to determine the influence of blood transfusion on the incidence of M-P V antibodies, cases were selected whose history of blood transfusions was well documented. Absence of circle means that the second test was not performed. Each symbol relates to one patient, except that patients studied before and after transplantation are represented by two symbols linked by a dotted line. (a) This patient had no antibodies Io months before transplantation but acquired antibodies 3 months before transplantation; IO other patients were followed during a similar period of time, 4 persistently showed antibodies to M-P V and 6 remained free of these antibodies.
No correlation between frequency of blood transfusions and presence of M-P V antibodies was found (Table 4) When antibodies to BeV syncytium-forming units, or to VSV (BeV) pseudotypes were studied, the frequency of positive results did not vary significantly according to the type of disease or to the graft status. Antibodies to SSV syncytium-forming units were also evenly distributed among the groups. Antibodies to each of the three viruses were specific since no statistical correlation was found between positive tests (Table 5) .
Demonstration of complement-dependent cytotoxic antibodies to M-P V producing cells
About an equal number of sera with and without antibodies to M-P V syncytium-forming units were selected and assayed for the presence of complement-dependent antibodies to 51Cr-labelled HeLa cells with or without M-P V. Patients' sera were compared to those of ~o children. None of the latter sera released significantly more sxCr than did complement alone. Examples of three different positive results are shown in Table 6 . Serum from patient P.A., was cytotoxic to HeLa (M-P V) cells up to the dilution ~ : IOO, with no activity on non-infected HeLa cells. Serum from patient D.R. was the only serum of the series which showed a prozone effect, with cytotoxic sp. act. on HeLa (M-P V) cells at dilution I" IOOO and not at ~ : Io. Finally, patient F.R. serum caused the release of SlCr from both HeLa (M-P V) cells and HeLa cells free of oncornavirus, showing non-specific anticellular toxicity.
It is not possible to evaluate the frequency of cytotoxic anticellular antibodies and of anti-M-P V antigens antibodies among the groups of patients before and after graft, because the sera were not randomly selected. Two equal series were chosen, on the criterion of presence or absence of antibodies to M-P V. This procedure was adopted with the aim of investigating the correlation between the presence of neutralizing and cytotoxic antibodies (Table 7) . There was a positive correlation since 6~ ~ of the sera with neutralizing anti- * Sera at final dilutions I:IO were incubated with the pseudotypes VSV (M-P V) or VSV (BeV) and residual virus infectivity was titrated on chick embryo fibroblasts.
t After incubation with sera I:Io, the oncomaviruses M-P V and BeV were titrated for syncytium formation on KC cells, and SSV was titrated on XC cells.
Number of individuals tested. § Per cent of sera with neutralizing activity. Ratio of sera positive for neutralization of BeV units to sera negative for neutralization of M-P V.
bodies to M-P V possessed specific antibodies to HeLa (M-P V) cells, as compared to I2 ~ among the sera without neutralizing antibodies (P < o.oo~).
DISCUSSION
Most fresh human sera cause non-specific lysis of many oncornaviruses (Welsch et aI. I976) . We show here that heated sera from some particular groups of patients specifically L. THIRY AND OTHERS neutralize either M-P V, or BeV, or SSV. This serum activity was not removed after adsorption of the sera with immune complexes, as represented by sheep erythrocytes sensitized with heated anti-sheep red blood cell rabbit serum, while such a treatment removes the lytic activity of fresh human serum (Thiry et al. I978c) .
Since the patients whom we studied had been submitted to blood transfusions and, in some cases, to kidney transplantation, it was necessary to check whether the activities of the patients' sera were not due to anticellular antibodies reacting with cell antigens present in the envelope of the oncornavirus and possibly also in that of the VSV (M-P V) pseudotypes.
This was rendered even more likely by our finding (Thiry et al. I978c ) that VSV (M-P V) pseudotypes obtained after VSV growth in HeLa cells producing M-P V were neutralized not only by anti-M-P V rabbit antisera, but also by a serum raised against HeLa cells free of oncornaviruses. Actually, neutralization by the anticellular sera was only observed when the VSV (M-P V) pseudotypes were titrated in HeLa cells and not when p.f.u, of the pseudotypes were counted in chick embryo fibroblasts. These cells were therefore used to minimize the risk of detecting anticellular antibodies to the pseudotypes in human sera. In addition it was demonstrated that adsorption of the human sera with HeLa cells, NC37 cells, dog cells or human foetal cells did not remove the activity of the sera towards the pseudotypes and the syncytium-forming units. It has been shown that humans possess natural antibodies to a calf serum antigen which is incorporated into the membrane of cells grown in tissue culture (Irie et al. ~974) and that this calf serum antigen is also present on the surface of oncornaviruses grown in these cells (Snyder & Fox, t978) . We feel that persistence of serum activities after adsorption on various cells grown in calf serum rules out the possibility that neutralization of oncornaviruses described here was due to antibodies directed against calf serum components. There is still the possibility that the oncornaviruses induced the expression or unmasking of some cellular antigens not detected in uninfected cells and that these cell antigens were taken up in the envelope of the virions. It is nevertheless clear that the three M-P V, BeV and SSV antigens were each a distinct product, since no statistical correlation was found between the presence of antibodies to the three antigens, among human sera.
Moreover, transfusions of human blood cells from unrelated donors were apparently not the clinical events which triggered formation of the antibodies demonstrated here, since four patients had M-P V antibodies prior to any transfusion and since the incidence of these antibodies did not increase with the number of transfusions administered. The grafted kidney might represent a source of M-P V antigen. There was a high rate of seroconversions, when sera from the patients were monitored before and after kidney transplantation, at 2 to 4 month intervals. It is not known, however, how many seroconversions would have been recorded if all patients had been tested every three months before transplantation. Patients receiving a pair of kidneys from the same cadaver are now being studied.
Was, then, the frequency of M-P V antibodies related to the disease ? This frequency was higher in patients with chronic glomerulonephritis than in those with other renal diseases. However, we did not find these antibodies in three patients with freshly discovered symptoms of disseminated lupus erythematosus. Whether immunodepression related to uraemia is correlated with appearance of M-P V antibodies remains to be elucidated.
Thus, the origin of the M-P V-associated antigen which elicited an immune response in the patients studied here remains unclear. No evidence has been presented in the literature that human individuals have cells containing M-P V genetic information, except that 7oS RNA possessing detectable homology to the RNAs of M-P V and of mouse mammary tumour virus has been described in human breast cancer (Ohno et al. I977) . There is a general agreement that M-P V is not endogenous in man. We did not find serum activity against M-P V in young children but this is not a proof of the exogenous origin of M-P V in man since antibodies to endogenous viruses may be acquired with ageing. On the other hand, no evidence has been presented for the occurrence of exogenous M-P V infections in man, although this virus multiplies freely in human cells. No precipitating antibodies to the labelled protein p25 of M-P V were found in various groups of human individuals (Charman et al. I977) of which ~4 had disseminated lupus erythematosus. The differences between these results and ours may be due to the types of patients studied and their therapy, or to the methods of antibody detection. The three tests which we used presumably detected antibodies to external or envelope proteins of M-P V. In contrast, our observation that a proportion of adults had antibodies to either BeV or to SSV is in agreement with published data, which were obtained by methods different from the ones used here, a fact which may account for the differences in antibody incidences. Using a radioimmunoassay with disrupted virions, antibodies to BeV and to SSV were found in lOO ~o and 46 ~o of adults, respectively (Kurth et al. I977 ); a high proportion of SSV antibodies was also found in a similar assay with whole virions (Snyder et al. 1976 ). Radioimmunoassays may be expected to be more sensitive than the neutralization tests applied in this study. Antibodies to SSV antigens were also found using cells productively infected with the virus, and studied by an indirect immunoelectron microscopy assay (Aoki et al. 1976 ) . In contrast, radioimmunoassays with the purified proteins p3o and gp7 o of SSV did not detect precipitating antibodies in various groups of patients, including 35 cases of lupus erythematosus (Stephenson & Aaronson, 1976) .
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